It reduces gastrointestinal motility, impeding the emptying of the stomacha function that keeps the patient feeling fuller for longer
Therefore, emphasis should be placed on combining energy-restriction with a high protein diet and physical activity, to provide the maximal anabolic stimulus, ensuring weight loss is not associated with loss of muscle mass, or, more importantly, muscle strength [67, 68]
1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
Share your thoughts in the comments section